发明授权
US08957068B2 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
有权
3-嘧啶-4-基 - 恶唑烷-2-酮作为突变体IDH的抑制剂
- 专利标题： 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
- 专利标题（中）： 3-嘧啶-4-基 - 恶唑烷-2-酮作为突变体IDH的抑制剂
-
申请号： US14347481申请日： 2012-09-26
-
公开(公告)号： US08957068B2公开(公告)日： 2015-02-17
- 发明人: Thomas Raymond Caferro , Young Shin Cho , Abran Q. Costales , Huangshu Lei , Francois Lenoir , Julian Roy Levell , Gang Liu , Mark G. Palermo , Keith Bruce Pfister , Martin Sendzik , Cynthia Shafer , Michael David Shultz , Troy Smith , James Clifford Sutton , Bakary-Barry Toure , Fan Yang , Qian Zhao
- 申请人： Thomas Raymond Caferro , Young Shin Cho , Abran Q. Costales , Huangshu Lei , Francois Lenoir , Julian Roy Levell , Gang Liu , Mark G. Palermo , Keith Bruce Pfister , Martin Sendzik , Cynthia Shafer , Michael David Shultz , Troy Smith , James Clifford Sutton , Bakary-Barry Toure , Fan Yang , Qian Zhao
- 申请人地址： CH Basel
- 专利权人： Novartis AG
- 当前专利权人： Novartis AG
- 当前专利权人地址： CH Basel
- 代理商 Stephen Johnson
- 国际申请： PCT/IB2012/055133 WO 20120926
- 国际公布： WO2013/046136 WO 20130404
- 主分类号： C07D413/04
- IPC分类号： C07D413/04 ; C07D413/14 ; A61K31/506 ; C07D487/04 ; C07D471/04 ; C07D487/08 ; C07D417/14 ; C07D498/10
摘要：
The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.
公开/授权文献
信息查询
